Last reviewed · How we verify
NCT05176548: Regamic
Registry of Patients with Suspected Amyloidosis in Heart Failure
trial testing Bone-cardiac scintigraphy in Heart Failure in 450 participants. Participants enrolled and being followed up; not accepting new ones.
31 March 2024
Quick facts
| Lead sponsor | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 450 |
| Start date | 15 January 2022 |
| Primary completion | 31 March 2024 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Bone-cardiac scintigraphy
Conditions studied
- Heart Failure — all drugs for Heart Failure →
Sponsor
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla — full company profile →
Who can join
18 and older, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Observational multicenter registry of cohorts with follow-up. Patients with heart failure, age ≥ 18 years, with clinical suspicion of cardiac amyloidosis and any LVEF value, treated in the field of Internal Medicine. Initially, a duration of two years was established to recruit at least 150 patients in the group with AC, and a follow-up of two years. Upon completion of the two years of follow-up, the continuity or completion of the registry will be assessed.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05176548
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Heart Failure
Currently open trials in the same condition.
- NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
- NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
- NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
- NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
- NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
Other Fundación Pública Andaluza para la gestión de la Investigación en Sevilla trials
Trials by the same sponsor.
- NCT05225961 — ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem · Phase 4 · completed
- NCT07521969 — Out-patiente Management for Gangrenous Acute Appendicitis: The PENDI-CSI II Randomized Clinical Trial. · NA · recruiting
- NCT07153406 — Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients · Phase 3 · not yet recruiting
- NCT07353424 — A Multicenter Randomized Clinical Trial Compared With Standard Clinical Practice to Evaluate the Efficacy of a Polypheno · NA · recruiting
- NCT06602310 — Utility of Preanestes@s2.0, a Web Based Application for Preoperative Assessment. · NA · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05176548 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
- Last refreshed: 1 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05176548.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing